Stop Superbugs Act
The source supplies the latest action, but no lifecycle stage.
Latest action (4 Aug 2026): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
What this bill does
The Stop Superbugs Act would direct the National Institutes of Health's infectious disease institute to award a competitive grant to the Antibiotic Resistance Leadership Group, an existing clinical research network focused on drug-resistant infections. The grant would fund four specific activities: speeding up recruitment of participants for clinical trials, conducting outreach to recruit trial participants in community settings, coordinating the pairing of new diagnostic tools with new drug treatments during trials, and developing better methods for capturing patient-reported outcomes in research studies. The bill authorizes "such sums as may be necessary" rather than a fixed dollar amount, leaving the actual funding level to future appropriations decisions.
The bill primarily affects the research infrastructure around antibiotic-resistant infections ("superbugs") — researchers, clinical trial sites, and communities that participate in trials would be the direct beneficiaries, with potential downstream effects on the pace of development of new antibiotics and diagnostics.
The bill was introduced in the Senate on August 4, 2026, by Senator Maggie Hassan (D-NH) with Senator Roger Marshall as a cosponsor. It has been read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions, where it would need to be considered and voted on before it could advance to the full Senate. It has not yet received a committee vote or floor action.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
4 Aug 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Common questions
- What does S. 5237 do?
- The Stop Superbugs Act would direct the National Institutes of Health's infectious disease institute to award a competitive grant to the Antibiotic Resistance Leadership Group, an existing clinical research network focused on drug-resistant infections. The grant would fund four specific activities: speeding up recruitment of participants for clinical trials, conducting outreach to recruit trial participants in community settings, coordinating the pairing of new diagnostic tools with new drug treatments during trials, and developing better methods for capturing patient-reported outcomes in research studies. The bill authorizes "such sums as may be necessary" rather than a fixed dollar amount, leaving the actual funding level to future appropriations decisions. The bill primarily affects the research infrastructure around antibiotic-resistant infections ("superbugs") — researchers, clinical trial sites, and communities that participate in trials would be the direct beneficiaries, with potential downstream effects on the pace of development of new antibiotics and diagnostics. The bill was introduced in the Senate on August 4, 2026, by Senator Maggie Hassan (D-NH) with Senator Roger Marshall as a cosponsor. It has been read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions, where it would need to be considered and voted on before it could advance to the full Senate. It has not yet received a committee vote or floor action.
- Has S. 5237 become law?
- The source does not supply a confirmed lifecycle stage for S. 5237. Check the latest action and official source below.
- Who sponsored S. 5237?
- S. 5237 was sponsored by Sen. Hassan, Margaret Wood [D-NH] (D-NH), with 1 cosponsor.
- What's the latest action on S. 5237?
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (4 Aug 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Sen. Hassan, Margaret Wood [D-NH]
Keep Food Containers Safe from PFAS Act of 2026
Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act
Addiction Grants Modernization Act
Improving CARE for Youth Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.